|
1
|
Drago JZ, Modi S and Chandarlapaty S:
Unlocking the potential of antibody-drug conjugates for cancer
therapy. Nat Rev Clin Oncol. 18:327–344. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Coates JT, Sun S, Leshchiner I, Thimmiah
N, Martin EE, McLoughlin D, Danysh BP, Slowik K, Jacobs RA,
Rhrissorrakrai K, et al: Parallel genomic alterations of antigen
and payload targets mediate therapeutic failure of multiple
antibody-drug conjugates. Cancer Discov. 11:2436–2445. 2021.
|
|
3
|
Hao Y and Song Z: Mechanisms of resistance
to antibody-drug conjugates in cancer therapy: Molecular basis and
therapeutic strategies. Cancer Drug Resist. 8(59)2025.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Camidge DR, Bar J, Horinouchi H, Goldman
J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C,
et al: Telisotuzumab vedotin monotherapy in patients with
previously treated c-Met protein-overexpressing advanced
nonsquamous EGFR-wildtype non-small cell lung cancer in the phase
II LUMINOSITY trial. J Clin Oncol. 42:3000–3011. 2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shitara K, Bang YJ, Iwasa S, Sugimoto N,
Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, et al:
Trastuzumab deruxtecan in previously treated HER2-positive gastric
cancer. N Engl J Med. 382:2419–2430. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Fenton MA, Tarantino P and Graff SL:
Sequencing antibody drug conjugates in breast cancer: exploring
future roles. Curr Oncol. 30:10211–10223. 2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ogitani Y, Aida T, Hagihara K, Yamaguchi
J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, et
al: DS-8201a, a novel HER2-targeting ADC with a novel DNA
topoisomerase I inhibitor, demonstrates a promising antitumor
efficacy with differentiation from T-DM1. Clin Cancer Res.
22:5097–5108. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Loganzo F, Sung M and Gerber HP:
Mechanisms of resistance to antibody-drug conjugates. Mol Cancer
Ther. 15:2825–2834. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bardia A, Hurvitz S, Tolaney SM, Loirat D,
Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB,
et al: Sacituzumab govitecan in metastatic triple-negative breast
cancer. N Engl J Med. 384:1529–1541. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kovtun YV, Audette CA, Mayo MF, Jones GE,
Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, et al:
Antibody-drug conjugates designed to eradicate tumors with
multidrug resistance. Cancer Res. 70:2528–2537. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hamblett KJ, Senter PD, Chace DF, Sun MM,
Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski
RF, et al: Effects of drug loading on the antitumor activity of a
monoclonal antibody drug conjugate. Clin Cancer Res. 10:7063–7070.
2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cortés J, Kim SB, Chung WP, Im SA, Park
YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, et al: Trastuzumab
deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J
Med. 386:1143–1154. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mai N, Klar Lieberman MM, Ferraro E,
Bromberg M, Chen Y, Razavi P, Modi S, Chandarlapaty S, Walsh EM and
Drago JZ: Sequential antibody-drug conjugate therapy in patients
with metastatic breast cancer treated with sacituzumab govitecan
and trastuzumab deruxtecan. JCO Precis Oncol.
9(e2400898)2025.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Powles T, Rosenberg JE, Sonpavde GP,
Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D,
Wu C, et al: Enfortumab vedotin in previously treated advanced
urothelial carcinoma. N Engl J Med. 384:1125–1135. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tagawa ST, Balar AV, Petrylak DP,
Kalebasty AR, Loriot Y, Fléchon A, Jain RK, Agarwal N, Bupathi M,
Barthelemy P, et al: TROPHY-U-01: A phase II open-label study of
sacituzumab govitecan in patients with metastatic urothelial
carcinoma progressing after platinum-based chemotherapy and
checkpoint inhibitors. J Clin Oncol. 39:2474–2485. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen
R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M,
Pérol M, et al: Datopotamab deruxtecan versus docetaxel for
previously treated advanced or metastatic non-small cell lung
cancer: The randomized, open-label phase III TROPION-Lung01 study.
J Clin Oncol. 43:260–272. 2025.PubMed/NCBI View Article : Google Scholar
|
